Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.54, Briefing.com reports. The business had revenue of $0.25 million for the quarter. Dicerna Pharmaceuticals’s revenue for the quarter was up 2400.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.75) earnings per share.

Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) opened at 3.16 on Friday. The stock’s market cap is $65.71 million. The stock’s 50 day moving average is $3.47 and its 200-day moving average is $3.10. Dicerna Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $6.10.

Several hedge funds have recently modified their holdings of the company. Bourgeon Capital Management LLC boosted its stake in shares of Dicerna Pharmaceuticals by 188.9% in the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 25,500 shares during the last quarter. Paloma Partners Management Co raised its position in Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock valued at $544,000 after buying an additional 53,131 shares during the period. Sabby Management LLC raised its position in Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 100,000 shares during the period. UBS Group AG raised its position in Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 1,599 shares during the period. Finally, Renaissance Technologies LLC raised its position in Dicerna Pharmaceuticals by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 408,682 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 84,682 shares during the period. Institutional investors and hedge funds own 55.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Dicerna Pharmaceuticals, Inc. (DRNA) Issues Earnings Results” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/dicerna-pharmaceuticals-inc-drna-issues-earnings-results-misses-expectations-by-0-47-eps/1470890.html.

A number of research firms have weighed in on DRNA. ValuEngine cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 23rd. Finally, Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $5.88.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.